Midday Market Movers: Rogers Earnings Beat, United Therapeutics Patent Win, Moderna Downgrade Among Notable Shifts

Rogers, a circuit materials manufacturer, surged 10% midday after providing full-year earnings guidance of approximately $3.80 per share, excluding certain items, above the FactSet consensus of $3.65. United Therapeutics rose 15% following a U.S. District Court ruling in Delaware that found Liquidia infringed on its patent; Liquidia shares plunged roughly 25% before trading was halted. Jabil declined more than 7% despite fiscal fourth-quarter results that beat estimates, with adjusted earnings of $4.40 per share on revenue of $10.62 billion, though guidance came in above estimates. Concentrix gained 5% on adjusted third-quarter earnings above expectations, but current-quarter Non-GAAP EPS and revenue guidance fell short as the company cited AI transition headwinds. Moderna dropped 7% after Citi downgraded the stock to sell, citing a price target 60% below Tuesday’s close and an unjustified valuation. FormFactor rose 8% after Deutsche Bank initiated coverage with a buy rating, highlighting the company’s growing role as the second source of probe cards for Nvidia GPUs at TSMC. Cal-Maine Foods slipped 2% following a fiscal first-quarter loss of $1.26 per share, wider than the expected loss of 77 cents.

Source link